Cargando…
Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Results from registry studies suggest that harnessing Natural Killer (NK) cell reactivity mediated through Killer cell Immunoglobulin-like Receptors (KIR) could reduce the risk of relapse after allogeneic Hematopoietic Cell Transplantation (HCT). Several competing models have been developed to class...
Autores principales: | Schetelig, Johannes, Baldauf, Henning, Koster, Linda, Kuxhausen, Michelle, Heidenreich, Falk, de Wreede, Liesbeth C., Spellman, Stephen, van Gelder, Michel, Bruno, Benedetto, Onida, Francesco, Lange, Vinzenz, Massalski, Carolin, Potter, Victoria, Ljungman, Per, Schaap, Nicolaas, Hayden, Patrick, Lee, Stephanie J., Kröger, Nicolaus, Hsu, Kathy, Schmidt, Alexander H., Yakoub-Agha, Ibrahim, Robin, Marie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851088/ https://www.ncbi.nlm.nih.gov/pubmed/33542712 http://dx.doi.org/10.3389/fimmu.2020.584520 |
Ejemplares similares
-
Corrigendum: Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
por: Schetelig, Johannes, et al.
Publicado: (2021) -
Estimation of German KIR Allele Group Haplotype Frequencies
por: Solloch, Ute V., et al.
Publicado: (2020) -
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
por: Schetelig, Johannes, et al.
Publicado: (2018) -
Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection
por: Heidenreich, Silke, et al.
Publicado: (2017) -
Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2020)